FR2444713B1 - - Google Patents

Info

Publication number
FR2444713B1
FR2444713B1 FR7835588A FR7835588A FR2444713B1 FR 2444713 B1 FR2444713 B1 FR 2444713B1 FR 7835588 A FR7835588 A FR 7835588A FR 7835588 A FR7835588 A FR 7835588A FR 2444713 B1 FR2444713 B1 FR 2444713B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7835588A
Other languages
French (fr)
Other versions
FR2444713A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Priority to FR7835588A priority Critical patent/FR2444713A1/fr
Priority to CH1099879A priority patent/CH646456A5/fr
Priority to GB7943491A priority patent/GB2034323B/en
Priority to BE2/58277A priority patent/BE880670A/fr
Priority to DE19792950995 priority patent/DE2950995A1/de
Priority to OA56977A priority patent/OA06416A/xx
Publication of FR2444713A1 publication Critical patent/FR2444713A1/fr
Application granted granted Critical
Publication of FR2444713B1 publication Critical patent/FR2444713B1/fr
Priority to US08/347,162 priority patent/US6225458B1/en
Priority to US08/369,998 priority patent/US6096879A/en
Priority to US08/478,853 priority patent/US6416996B1/en
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR7835588A 1978-12-18 1978-12-18 Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant Granted FR2444713A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR7835588A FR2444713A1 (fr) 1978-12-18 1978-12-18 Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant
CH1099879A CH646456A5 (fr) 1978-12-18 1979-12-12 Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant.
BE2/58277A BE880670A (fr) 1978-12-18 1979-12-18 Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant
DE19792950995 DE2950995A1 (de) 1978-12-18 1979-12-18 Verfahren zur herstellung einer dna, welche das genom des hepatitis b virus sowie den vektor umfasst, der dieses genom enthaelt
GB7943491A GB2034323B (en) 1978-12-18 1979-12-18 Production of dna comprising the b hepatitis viral genome
OA56977A OA06416A (fr) 1978-12-18 1979-12-18 Procédé de production d'un ADN comprenant le genome du virus de l'hépatite B et vecteur le comportant.
US08/347,162 US6225458B1 (en) 1978-12-18 1994-11-23 Process for the production of DNA comprising the genome of the hepatitis B virus and vector including it
US08/369,998 US6096879A (en) 1978-12-18 1995-01-09 Nucleotide sequence comprising the genome of hepatitis B virus, nucleotide sequence coding the surface antigen of the hepatitis B virus, vectors containing the nucleotide sequences, process for the preparation thereof, and antigen obtained thereby
US08/478,853 US6416996B1 (en) 1978-12-18 1995-06-07 Nucleotide sequence comprising the genome of hepatitis b virus, nucleotide sequence coding the surface antigen of the hepatitis b virus, vectors containing the nucleotide sequences, process for the preparation thereof, and antigen obtained thereby

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7835588A FR2444713A1 (fr) 1978-12-18 1978-12-18 Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant

Publications (2)

Publication Number Publication Date
FR2444713A1 FR2444713A1 (fr) 1980-07-18
FR2444713B1 true FR2444713B1 (OSRAM) 1981-02-06

Family

ID=9216265

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7835588A Granted FR2444713A1 (fr) 1978-12-18 1978-12-18 Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant

Country Status (6)

Country Link
BE (1) BE880670A (OSRAM)
CH (1) CH646456A5 (OSRAM)
DE (1) DE2950995A1 (OSRAM)
FR (1) FR2444713A1 (OSRAM)
GB (1) GB2034323B (OSRAM)
OA (1) OA06416A (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480779B2 (fr) * 1979-08-30 1986-07-18 Anvar Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur
EP0182442B2 (en) * 1978-12-22 1996-04-03 Biogen, Inc. Recombinant DNA molecules and their method of production
US6297355B1 (en) 1978-12-22 2001-10-02 Biogen, Inc. Polypeptides displaying HBV antigenicity or hbv antigen specificity
DK171727B1 (da) * 1978-12-22 1997-04-14 Biogen Inc Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
US5196194A (en) * 1979-05-24 1993-03-23 The Regents Of The University Of California Vaccines containing Hepatitis B S-protein
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6835557B1 (en) 1980-01-08 2004-12-28 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
DE3176404D1 (en) * 1980-04-22 1987-10-08 Pasteur Institut Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine
US4393133A (en) * 1980-06-12 1983-07-12 The Wistar Institute Of Anatomy And Biology Human hepatoma derived cell line, process for preparation thereof, and uses therefor
US5145782A (en) * 1980-12-08 1992-09-08 The Regents Of The University Of California DNA expression vector suitable for direct expression of a foreign gene
US4446237A (en) * 1981-03-27 1984-05-01 Life Technologies, Inc. Method for detection of a suspect viral deoxyribonucleic acid in an acellular biological fluid
EP0062286A1 (en) * 1981-03-31 1982-10-13 Albert Einstein College Of Medicine Of Yeshiva University Diagnostic test for hepatitis B virus
US4711955A (en) * 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US4769238A (en) 1981-08-04 1988-09-06 The Regents Of The University Of California Synthesis of human virus antigens by yeast
US4803164A (en) * 1981-08-31 1989-02-07 Genentech, Inc. Preparation of hepatitis b surface antigen in yeast
ZW18282A1 (en) 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
AU8746582A (en) * 1981-09-02 1983-03-10 Biogen N.V. Hepatitis b virus e type antigen
FI63596C (fi) * 1981-10-16 1983-07-11 Orion Yhtymae Oy Mikrobdiagnostiskt foerfarande som grundar sig pao skiktshybridisering av nukleinsyror och vid foerfarandet anvaenda kombinationer av reagenser
US4480040A (en) * 1981-12-03 1984-10-30 The United States Of America As Represented By The Secretary Of Agriculture Sensitive and rapid diagnosis of viroid diseases and viruses
JPS5931799A (ja) * 1982-08-16 1984-02-20 Science & Tech Agency Ｂ型肝炎ウイルス遺伝子を組込んだ組換えプラスミド
USRE35491E (en) * 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4820642A (en) * 1983-04-04 1989-04-11 The Regents Of The University Of California Amplified expression vector
FR2560995B1 (fr) * 1984-03-07 1988-02-19 Pasteur Institut Reactifs et necessaires pour le dosage quantitatif d'un acide nucleique viral dans un milieu biologique et procede de dosage de cet acide nucleique viral
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
DE69231693T2 (de) * 1991-12-23 2001-05-31 Bayer Corp., East Walpole Hbv amplifizierungssonden zur verwendung in hybridisierungssandwichassay in der lösungsphase
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
AU779689B2 (en) 1999-06-16 2005-02-03 Icos Corporation Human poly(ADP-ribose) polymerase 2 materials and methods
JP2004515233A (ja) 2000-11-01 2004-05-27 イルーシス セラポーティクス，インコーポレーテッド タンパク質トランススプライシングによる二重特異性分子の作製方法
AU2006242225B2 (en) 2005-04-29 2012-01-12 Rockefeller University Human microRNAs and methods for inhibiting same
JP2009507030A (ja) 2005-09-01 2009-02-19 セルジーン・コーポレーション ワクチン及び抗感染症療法のための免疫調節性化合物の免疫学的使用
CA2691785C (en) 2007-06-27 2017-01-10 Marine Polymer Technologies Inc. Complexes of il-15 and il-15ralpha and uses thereof
WO2010017248A2 (en) 2008-08-04 2010-02-11 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
EP2389443B1 (en) 2009-01-23 2018-11-14 Roger Williams Hospital Retroviral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
US9216189B2 (en) 2010-01-25 2015-12-22 Icahn School Of Medicine At Mount Sinai Antibodies which bind type I cannabinoid receptor/angiotensis II receptor heteromers
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
HK1205952A1 (en) 2012-02-16 2015-12-31 The Penn State Research Foundation Modulators of acyl-coa lysocardiolipin acyltransferase 1 ( alcat1) and uses thereof
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
WO2014066527A2 (en) 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
WO2016018920A1 (en) 2014-07-29 2016-02-04 Admune Therapeutics Llc Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
EP3212221B1 (en) 2014-10-29 2023-12-06 Massachusetts Eye & Ear Infirmary Efficient delivery of therapeutic molecules in vitro and in vivo
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
JP7320601B2 (ja) 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
US11786592B2 (en) 2021-05-19 2023-10-17 The University Of Hong Kong Compositions of cardiolipin adjuvants and methods of use thereof
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
US20230364227A1 (en) 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Poxvirus adjuvant for t-cell vaccination

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521032A (en) * 1974-08-08 1978-08-09 Ici Ltd Biological treatment
DE2712615A1 (de) * 1977-03-18 1978-09-21 Max Planck Gesellschaft Verfahren zur herstellung von filamentoesen phagen als vektor fuer synthetische rekombinate

Also Published As

Publication number Publication date
FR2444713A1 (fr) 1980-07-18
GB2034323B (en) 1983-01-12
DE2950995C2 (OSRAM) 1991-05-02
DE2950995A1 (de) 1980-07-24
BE880670A (fr) 1980-06-18
GB2034323A (en) 1980-06-04
OA06416A (fr) 1981-09-30
CH646456A5 (fr) 1984-11-30

Similar Documents

Publication Publication Date Title
FR2413106B1 (OSRAM)
FR2414140B3 (OSRAM)
FR2416333B1 (OSRAM)
FR2417123B1 (OSRAM)
FR2415446B1 (OSRAM)
AU3898778A (OSRAM)
FR2413766B3 (OSRAM)
DK142649C (OSRAM)
AU3892778A (OSRAM)
AU73950S (OSRAM)
DK132178A (OSRAM)
BG25902A1 (OSRAM)
BG25972A1 (OSRAM)
BG26006A1 (OSRAM)
BG26014A1 (OSRAM)
BG25836A1 (OSRAM)
BG25843A1 (OSRAM)
BG25898A1 (OSRAM)
BG25955A1 (OSRAM)
BG26009A1 (OSRAM)
BG25921A1 (OSRAM)
BG25842A1 (OSRAM)
BG26022A1 (OSRAM)
BG25956A1 (OSRAM)
BG25871A1 (OSRAM)